Policlinico “Tor Vergata”, Università degli Studi di Roma TOR VERGATA

At Policlinico “Tor Vergata” investigators are evaluating new therapies aimed at reducing cardiovascular risk and improving metabolic health. Studies focus on preventing events, lowering harmful lipids, and managing obesity‑related complications.

• ASCVD (Atherosclerotic Cardiovascular Disease)
• Heart Failure (including HFpEF and HFmrEF)
• Hypercholesterolemia
• Obesity and overweight
• Type 2 Diabetes Mellitus
• Chronic kidney disease with systemic inflammation

The site supports over 230 active trials with a multidisciplinary team of ten investigators.

Research in Neoplasms and blood cancers aims to test innovative targeted agents and combination regimens to improve survival and quality of life for patients with solid tumours and hematologic malignancies.

• Breast cancer
• Prostate cancer (high‑risk and metastatic)
• Colorectal cancer (including metastatic disease)
• Acute Myeloid Leukemia (including FLT3‑mutated AML)
• Chronic Lymphocytic Leukemia
• Multiple Myeloma
• Diffuse Large B‑Cell Lymphoma
• High‑risk Myelodysplastic Syndromes

Oncology trials at the centre integrate surgical, radiologic, and systemic approaches to advance personalized cancer care.

In the field of Digestive System Diseases, studies are designed to assess disease‑modifying therapies for inflammatory bowel conditions and metabolic liver disorders, with an emphasis on achieving deep remission and preventing complications.

• Crohn’s Disease
• Ulcerative Colitis
• Metabolic Dysfunction‑Associated Steatotic Liver Disease (NASH)
• Chronic liver disease with fibrosis
• Diabetic Foot Ulcer
• Colon cancer
• Small bowel adenocarcinoma

Trials often incorporate endoscopic and imaging endpoints to evaluate mucosal healing and liver fibrosis regression.

The centre’s Neurological Disorders program investigates novel agents that target neurodegeneration, seizure control, and sleep‑wake regulation, while the Mental Disorders portfolio focuses on improving cognition and mood.

• Alzheimer’s disease (mild to moderate)
• Parkinson’s disease
• Multiple Sclerosis (relapsing‑remitting, primary progressive, secondary progressive)
• Epilepsy (refractory focal and generalized)
• Narcolepsy (with and without cataplexy)
• Irritability in autism spectrum disorder
• Mild cognitive impairment

Outcomes include clinical scales, MRI biomarkers, and quality‑of‑life measures.

Studies under Immune System Diseases explore biologic and small‑molecule therapies intended to modulate immune pathways, aiming to reduce disease activity and organ damage in chronic inflammatory conditions.

• Atopic Dermatitis
• Psoriatic Arthritis
• Hidradenitis Suppurativa
• Chronic Graft‑Versus‑Host Disease
• Primary Immune Thrombocytopenia
• Generalized Myasthenia Gravis
• Hereditary Angioedema
• Chronic Inflammatory Demyelinating Polyneuropathy

The trials frequently assess patient‑reported outcomes and biomarkers of immune activation.

The Viral and Bacterial Infections portfolio targets both chronic viral illnesses and acute bacterial challenges, evaluating antiviral potency, immune restoration, and prophylactic strategies.

• Human Immunodeficiency Virus (HIV) infection
• Chronic Hepatitis B
• Cytomegalovirus infection
• Bacterial infections and mycoses
• Recurrent Lower Respiratory Tract Infections

Research includes virologic suppression endpoints and safety monitoring in immunocompromised populations.

In the Eye Diseases area, trials assess innovative intravitreal agents and topical treatments to preserve visual function and halt disease progression in retinal and optic‑nerve disorders.

• Age‑Related Macular Degeneration (dry and neovascular forms)
• Geographic Atrophy
• Diabetic Macular Edema
• Glaucoma
• Macular edema secondary to retinal vein occlusion
• Open‑angle glaucoma visual‑field preservation

Primary outcomes involve best‑corrected visual acuity and retinal imaging biomarkers.

The Skin and Connective Tissue Diseases program evaluates topical and systemic agents designed to clear lesions, reduce inflammation, and improve skin quality in chronic dermatoses.

• Acne vulgaris
• Actinic Keratosis (face and scalp)
• Atopic Dermatitis
• Plaque Psoriasis (moderate to severe)
• Prurigo Nodularis
• Hidradenitis Suppurativa
• Neurodermatitis

Efficacy is measured by lesion‑clearance rates and patient‑reported itch scores.

Research in Respiratory Tract Diseases and interstitial lung pathology focuses on reducing exacerbations, improving lung function, and slowing fibrotic progression.

• Chronic Obstructive Pulmonary Disease (COPD)
• Idiopathic Pulmonary Fibrosis
• Progressive Fibrosing Interstitial Lung Diseases
• Acute Respiratory Distress Syndrome
• Chronic bronchitis
• Recurrent Lower Respiratory Tract Infections

Trials incorporate spirometry, high‑resolution CT, and patient‑reported symptom scales.

The centre’s work on Genetic Phenomena and ultra‑rare conditions seeks to uncover disease mechanisms and test targeted therapies for disorders with limited treatment options.

• VEXAS syndrome
• Myotonic Dystrophy (type 1 and type 2)
• Hereditary Angioedema (type I/II)
• Narcolepsy Type 1 (with cataplexy)
• Rare metabolic disorders associated with MDS

Outcomes often involve genetic biomarkers, disease‑specific activity scores, and safety profiling.